Capital Investment in High Value-Added Products, New Technologies and Environmental Initiatives
First written in FY2016. 14 of 31 entries say "Restated". Latest entry: FY2026.
The whole theme swung hardest in 2020: 2 of 14 companies on the "Worse" side.
10 other companies' latest entry also says "Advanced".
- FY2026AdvancedAnnual report
「As a result, capital expenditures for the consolidated fiscal year amounted to ¥34,438 million.」
Capital expenditures increased from ¥18,381 million in the previous fiscal year to ¥34,438 million. The company invested ¥25,733 million in the chemical products business, as well as investing in manufacturing facilities and other assets in the functional chemicals, pharmaceuticals, medical and healthcare businesses. - FY2026-H1AdvancedAnnual report
「The Group's total capital expenditures during the interim consolidated accounting period amounted to ¥13,980 million. Net cash provided by operating activities increased by ¥12,255 million from the same period of the previous year, mainly due to a ¥2,453 million decrease in interim net income before tax and other adjustments, a ¥158 million decrease in working capital requirements, a ¥16,338 million increase in advances received, a ¥5,750 million increase in fixed assets related to accelerated equipment installation, and a ¥128 million increase in income taxes paid. The increase in advances received included ¥17,582 million in advances for defense-related facilities associated with accelerated equipment installation in the chemical products business.」
First-half capital expenditures totaled ¥13,980 million. In the chemical products business, the company disclosed a ¥5,750 million increase in fixed assets related to accelerated installation of defense-related facilities and ¥17,582 million in advances received. - FY2025AdvancedAnnual report
「Continuing from the previous consolidated fiscal year, the Group invested in (a) production facilities to meet growing demand for high-value-added products, (b) new production facilities developed through new technologies, and (c) facility renovations and other measures to reduce environmental impact. As a result, capital expenditures for the consolidated fiscal year amounted to ¥18,381 million.」
Capital investment continued, with capital expenditures for the fiscal year totaling ¥18,381 million. As of the fiscal year-end, planned investment in major facilities totaled ¥98,547 million, including explosives and pyrotechnics facilities at the Aichi Plant, within 日本工機㈱, and the Shirakawa Manufacturing Facility. - FY2025-H1Update and decrease in first-half capital expendituresAnnual report
「The Group's total capital expenditures during the interim consolidated accounting period amounted to ¥6,285 million. There were no material changes in the Group's major facilities or capital investment plans during the interim consolidated accounting period.」
First-half capital expenditures amounted to ¥6,285 million. The company stated that there were no material changes in its major facilities or capital investment plans. Purchases of property, plant and equipment and intangible assets decreased by ¥2,197 million year on year. - FY2024AdvancedAnnual report
「As a result, capital investment totaled ¥18,695 million in the fiscal year.」
The Group continued capital investment related to high-value-added products, new technologies, and environmental impact reduction, bringing capital investment to ¥18,695 million. As of the fiscal year-end, planned investment in major facilities totaled ¥20,776 million, including expansion of functional chemicals facilities and construction of new pharmaceutical, medical, and healthcare product facilities at the Aichi Site, as well as expansion of safety and disaster-prevention facilities at the Kawasaki Site. - FY2024-Q2First-half increase in spending on property, plant and equipment acquisitionsAnnual report
「Net cash used in investing activities increased by ¥7,137 million year on year, reflecting a ¥1,442 million decrease in proceeds from sales of investment securities and a ¥5,098 million increase in spending on purchases of property, plant and equipment and intangible assets, among other factors.」
While stating that there were no significant changes in major facilities or capital investment plans, the Group reported that spending on purchases of property, plant and equipment and intangible assets increased ¥5,098 million year on year. - FY2024-Q1RestatedAnnual report
「During the first-quarter cumulative period, there were no significant changes in the Group’s major facilities or capital investment plans.」
The Group states that there have been no significant changes in major facilities or capital investment plans. - FY2023-Q3RestatedAnnual report
「During the third-quarter cumulative period, there were no significant changes in the Group’s major facilities or capital investment plans.」
There have been no significant changes in major facilities or capital investment plans. - FY2023-Q2AdvancedAnnual report
「With the start-up of manufacturing facilities for DDS pharmaceutical formulation materials at the Kawasaki Site, we improved productivity and strengthened quality control to enhance the supply capacity of the life sciences business.」
Manufacturing facilities for DDS pharmaceutical formulation materials at the Kawasaki Site began operations, and the Group improved productivity and strengthened quality control. - FY2023-Q1RestatedAnnual report
「During the first-quarter cumulative period, there were no significant changes in the Group’s major facilities or capital investment plans.」
The disclosure states that there were no significant changes in major facilities or capital investment plans. - FY2022AdvancedAnnual report
「At our Group, comprising the Company and its consolidated subsidiaries, we made investments, as in the previous fiscal year, in (a) production facilities to meet expanding demand for high-value-added products, (b) new production facilities developed through new technologies, and (c) facility renovations and other projects to reduce environmental impact. As a result, capital investment totaled ¥5,735 million in the fiscal year.」
The Group continued capital investment related to high-value-added products, new technologies, and environmental impact reduction. As of the fiscal year-end, planned investment in major facilities totaled ¥3,222 million, including the quality and production management system at the Kawasaki Site and life sciences manufacturing facilities at the Aichi Site. - FY2022-Q3RestatedAnnual report
「During the third-quarter cumulative period, there were no significant changes in the Group’s major facilities or capital investment plans.」
The disclosure states that there were no significant changes in major facilities or capital investment plans. - FY2022-Q2AdvancedAnnual report
「Regarding “expansion into growth markets,” we proceeded with the expansion of manufacturing facilities for DDS pharmaceutical formulation materials at the Kawasaki Site to strengthen the production system for the life sciences business.」
To strengthen the production system for the life sciences business, the Group proceeded with expanding manufacturing facilities for DDS pharmaceutical formulation materials at the Kawasaki Site. - FY2022-Q1RestatedAnnual report
「During the first-quarter cumulative period, there were no significant changes in the Group’s major facilities or capital investment plans.」
The disclosure states that there were no significant changes in major facilities or capital investment plans. - FY2021AdvancedAnnual report
「As a result, capital investment totaled ¥8,432 million in the fiscal year.」
The Group continued capital investment related to high-value-added products, new technologies, and environmental impact reduction, bringing capital investment to ¥8,432 million. Investment totaled ¥4,653 million in functional chemicals, ¥2,106 million in life sciences, and ¥1,376 million in chemical products. - FY2021-Q3RestatedAnnual report
「During the third-quarter cumulative period, there were no significant changes in the Group’s major facilities or capital investment plans.」
The disclosure states that there were no significant changes in major facilities or capital investment plans. - FY2021-Q2RestatedAnnual report
「During the second-quarter cumulative period, there were no significant changes in the Group’s major facilities or capital investment plans.」
The disclosure states that there were no significant changes in major facilities or capital investment plans. - FY2021-Q1RestatedAnnual report
「During the first-quarter cumulative period, there were no significant changes in the Group’s major facilities or capital investment plans.」
The disclosure states that there were no significant changes in major facilities or capital investment plans. - FY2020AdvancedAnnual report
「As a result, capital investment totaled ¥8,085 million in the fiscal year.」
The Group continued capital investment related to high-value-added products, new technologies, and environmental impact reduction, with investment increasing from ¥5,956 million in the previous fiscal year to ¥8,085 million. It also outlined plans totaling ¥4,765 million for new construction and expansions at the Kinoura, Amagasaki, Chidori, and DDS (drug delivery system) plants, among others. - FY2020-Q3RestatedAnnual report
「During the third-quarter cumulative period, there were no significant changes in the Group’s major facilities or capital investment plans.」
The disclosure states that there were no significant changes in major facilities or capital investment plans. - FY2020-Q2Increase in spending on fixed-asset acquisitionsAnnual report
「Net cash used in investing activities increased by ¥1,145 million year on year, reflecting a ¥498 million decrease in spending on purchases of investment securities, a ¥443 million decrease in proceeds from sales of investment securities, and a ¥1,428 million increase in spending on purchases of property, plant and equipment and intangible assets, among other factors.」
Spending on purchases of property, plant and equipment and intangible assets increased ¥1,428 million year on year. At the same time, the disclosure states that there were no significant changes in major facilities or capital investment plans. - FY2020-Q1RestatedAnnual report
「During the first-quarter cumulative period, there were no significant changes in the Group’s major facilities or capital investment plans.」
The disclosure states that there were no significant changes in major facilities or capital investment plans. - FY2019AdvancedAnnual report
「At our Group, comprising the Company and its consolidated subsidiaries, we made investments, as in the previous fiscal year, in (a) production facilities to meet expanding supply and demand for high-value-added products, (b) new production facilities developed through new technologies, and (c) facility renovations and other projects to reduce environmental impact. As a result, capital investment totaled ¥5,956 million in the fiscal year.」
The Group continued capital investment related to high-value-added products, new technologies, and environmental impact reduction, bringing capital investment to ¥5,956 million. It also outlined capital investment plans from 2019 through 2020, including expansions at the Amagasaki and Kinoura plants and construction of an integrated facility. - FY2019-Q3RestatedAnnual report
「During the third-quarter cumulative period, there were no significant changes in the Group’s major facilities or capital investment plans.」
The disclosure states that there were no significant changes in major facilities or capital investment plans. - FY2019-Q2RestatedAnnual report
「To improve productivity, the Group is promoting investments in efficiency.」
The Group continues to make efficiency investments to improve productivity. No significant changes were reported in the capital investment plans. - FY2019-Q1RestatedAnnual report
「During the first-quarter cumulative period, there were no significant changes in the Group’s major facilities or capital investment plans.」
The disclosure states that there were no significant changes in major facilities or capital investment plans. - FY2018-Q2RestatedAnnual report
「We are also continuing to invest in efficiency improvements to raise productivity.」
The disclosure states that efficiency investments to improve productivity are continuing. - FY2017AdvancedAnnual report
「As a result, capital investment totaled ¥6,420 million in the fiscal year.」
The Group continued capital investment related to high-value-added products, new technologies, and environmental impact reduction, bringing capital investment for the fiscal year to ¥6,420 million. It also outlined plans to invest a total of ¥874 million to expand facilities at the Amagasaki and Kinoura plants. - FY2016First statedAnnual report
「At our Group, comprising the Company and its consolidated subsidiaries, we made investments, as in the previous fiscal year, in (a) production facilities to meet expanding supply and demand for high-value-added products, (b) new production facilities developed through new technologies, and (c) facility renovations and other projects to reduce environmental impact. As a result, capital investment totaled ¥4,965 million in the fiscal year.」
Capital investment totaled ¥4,965 million in the fiscal year. The Group also outlined plans for ¥3,186 million of investment from the following fiscal year onward, including at the Kinoura Plant and Kawasaki Site.